Send mail to Author

Correction: Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis (Article)

Please indicate your contact information and select, which author you want to contact.



 
 __   _     ______    _  __   __   __  __    __     ___    
| || | ||  /_   _//  | |/ //  \ \\/ // \ \\ / //   / _ \\  
| '--' ||   -| ||-   | ' //    \ ` //   \ \/ //   / //\ \\ 
| .--. ||   _| ||_   | . \\     | ||     \  //   |  ___  ||
|_|| |_||  /_____//  |_|\_\\    |_||      \//    |_||  |_||
`-`  `-`   `-----`   `-` --`    `-`'       `     `-`   `-`
 


Back to frontdoor view

OPUS4 Logo